Project description
New treatment for acute lung damage
Acute respiratory distress syndrome (ARDS) is a life-threatening condition in which lung injury leads to inflammation and fluid in the air sacs in the lungs, resulting in insufficient oxygen passing into the blood. It is the immediate cause of death of patients suffering from COVID-19. There are currently no authorised products for the treatment of ARDS in the EU. In this context, the EU-funded Impentri project is targeting the cause and trigger of the mortality associated with the condition through development of effective pharmacotherapy. It is actually an intravenous formulation of a chemotherapeutic drug. As a repurposed drug, it will reach human trials earlier. Overall, the project is expected to lower mortality.
Objective
Acute Respiratory Distress syndrome (ARDS) is a life threatening condition that affects 3 million people world-wide. With regards to the current coronavirus pandemic, ARDS is the immediate cause of death for patients suffering from this infection. 40% of the patients that suffer from the condition succumb to it and among the ones that survive, most of them face long-term physical and mental illness. The unreliable, costly, prolonged treatment options currently available are responsible for the high mortality observed in the condition. The treatments offer only relief from symptoms and manage the condition but are not curative. Exvastat is developing impentri as a reliable and effective pharmacotherapy for ARDS as it targets the cause and trigger of the mortality associated with the condition. It is an intravenous formulation of widely-used chemotherapeutic drug, Imatinib which has shown promising results in-vitro and clinical reports in ARDS like conditions. Being a repurposed drug, Impentri has the advantage of reaching human trials earlier than other drugs. With EIC funds Exvastat plans to register and successfully finish 50% of the PhaseII trials in ARDS patients. This would provide an opening for the drug to successfully finish further trials and its orphan drug status would guarantee early market entry. With Impentri Exvastat wants to lower mortality and provide better quality of life to patients suffering from ARDS
Fields of science
Keywords
Programme(s)
Funding Scheme
SME-2 - SME instrument phase 2Coordinator
PE28 2AF HUNTINGDON
United Kingdom
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.